Phase I Clinical study for cyberknife combined with PD1 antibody in the treatment of hilar lung cancer

Status

Recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800019560

Enrollment

Unknown

Registered

2018-11-18

Start date

2018-11-13

Completion date

Unknown

Last updated

2018-11-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

none small cell lung cancer

Interventions

Case series:Stereotactic radiotherapy combined with PD1 antibody

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients with primary or metastatic tumors of the eyes; 2. T3-4N0M0 NSCLC; T3-4N0M1; T3-4NX M0-1; 3. T3-4N0M0 NSCLC; T3-4N0M1(Oligo-metastases); T3-4NX M0-1(Local palliative treatment of symptoms caused by hilar lesions).

Exclusion criteria

Exclusion criteria: 1. Local lesions are not suitable for SRS; 2. Body poor constitution could not accept SRS; 3. PD1 antibody application contraindications.

Design outcomes

Primary

Measure	Time frame
toxicity;	—

Countries

China

Contacts

Public ContactZhuang Hongqing

Department of Radiation Oncology, Peking University Third Hospital

hongqingzhuang@163.com+86 13051776232

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026